These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 7493365)

  • 1. Review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's disease.
    Vriesendorp HM; Morton JD; Quadri SM
    Cancer Res; 1995 Dec; 55(23 Suppl):5888s-5892s. PubMed ID: 7493365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of radiolabeled polyclonal antiferritin in patients with Hodgkin's disease.
    Lai J; Quadri SM; Borchardt PE; Harris L; Wucher R; Askew E; Schweichel L; Vriesendorp HM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3315s-3323s. PubMed ID: 10541380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fractionated radiolabeled antiferritin therapy for patients with recurrent Hodgkin's disease.
    Vriesendorp HM; Quadri SM; Wyllie CT; Lai J; Borchardt PE; Harris L; Wucher R; Askew E; Schweichler L
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3324s-3329s. PubMed ID: 10541381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01.
    Vriesendorp HM; Herpst JM; Germack MA; Klein JL; Leichner PK; Loudenslager DM; Order SE
    J Clin Oncol; 1991 Jun; 9(6):918-28. PubMed ID: 2033428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
    Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioimmunotherapy of refractory or relapsed Hodgkin's lymphoma with 90Y-labelled antiferritin antibody.
    Decaudin D; Levy R; Lokiec F; Morschhauser F; Djeridane M; Kadouche J; Pecking A
    Anticancer Drugs; 2007 Jul; 18(6):725-31. PubMed ID: 17762404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment.
    Herpst JM; Klein JL; Leichner PK; Quadri SM; Vriesendorp HM
    J Clin Oncol; 1995 Sep; 13(9):2394-400. PubMed ID: 7666099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiolabeled immunoglobulin therapy in patients with Hodgkin's disease.
    Vriesendorp HM; Quadri SM
    Cancer Biother Radiopharm; 2000 Oct; 15(5):431-45. PubMed ID: 11155816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrence of Hodgkin's disease after indium-111 and yttrium-90 labeled antiferritin administration.
    Vriesendorp HM; Quadri SM; Andersson BS; Wyllie CT; Dicke KA
    Cancer; 1997 Dec; 80(12 Suppl):2721-7. PubMed ID: 9406730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
    Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Yttrium-90 and iodine-131 radioimmunoglobulin therapy of an experimental human hepatoma.
    Klein JL; Nguyen TH; Laroque P; Kopher KA; Williams JR; Wessels BW; Dillehay LE; Frincke J; Order SE; Leichner PK
    Cancer Res; 1989 Nov; 49(22):6383-9. PubMed ID: 2553255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of reagents for human radioimmunotherapy.
    Vriesendorp HM; Quadri SM; Stinson RL; Onyekwere OC; Shao Y; Klein JL; Leichner PK; Williams JR
    Int J Radiat Oncol Biol Phys; 1992; 22(1):37-45. PubMed ID: 1727128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
    DeNardo GL; O'Donnell RT; Shen S; Kroger LA; Yuan A; Meares CF; Kukis DL; DeNardo SJ
    J Nucl Med; 2000 May; 41(5):952-8. PubMed ID: 10809213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indium-111- and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice.
    Borchardt PE; Quadri SM; Freedman RS; Vriesendorp HM
    J Nucl Med; 1998 Mar; 39(3):476-84. PubMed ID: 9529295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.
    Knox SJ; Goris ML; Trisler K; Negrin R; Davis T; Liles TM; Grillo-López A; Chinn P; Varns C; Ning SC; Fowler S; Deb N; Becker M; Marquez C; Levy R
    Clin Cancer Res; 1996 Mar; 2(3):457-70. PubMed ID: 9816191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Centralized radiolabeling of antibodies for radioimmunotherapy.
    Colcher D
    J Nucl Med; 1998 Aug; 39(8 Suppl):11S-13S. PubMed ID: 9708565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial.
    DeNardo SJ; Kramer EL; O'Donnell RT; Richman CM; Salako QA; Shen S; Noz M; Glenn SD; Ceriani RL; DeNardo GL
    J Nucl Med; 1997 Aug; 38(8):1180-5. PubMed ID: 9255145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.